Study of OT-101 in Treating Myopia

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Myopia, Progressive

In brief

This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects

Key facts

Study ID
NCT04770610
Run by
Ocumension (Hong Kong) Limited
People needed
678
Starts
2021-04-01
Expected to finish
2027-04-01
Last updated by the study team
2023-08-08

Who can join

Age: 3 and older, up to 15. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.